Compare Domino's Pizza, Inc. (DPZ) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Merck & Co., Inc. — how do they compare? Domino's Pizza, Inc. trades at $350.36 (market cap $11.82B), while Merck & Co., Inc. trades at $131.32 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 27.2× Domino's Pizza, Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| DPZ | MRK | |
|---|---|---|
Market Cap | $11.82B | $321.77B |
Sector | Consumer Cyclical | Health |
52-Week High | $467.30 | $131.84 |
52-Week Low | $282.89 | $77.60 |
Enterprise Value | $16.78B | $368.53B |
Dividend Yield | 2.23% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $347.85, down 0.88% on the day, with mixed technical signals showing neutral overall momentum. The company reported three consecutive quarterly EPS misses but maintains strong profitability with 11.86% net margins and positive revenue growth. Recent news highlights product innovation with the launch of individual-sized pizzas and digital platform enhancements to drive customer engagement.
Wall Street maintains a bullish stance with 54% buy ratings and a $371.67 price target, representing 7% upside potential. Key risks include elevated debt levels, competitive pressures, and consumer spending sensitivity. The stock offers value through consistent dividends and operational efficiency, though near-term execution on sales growth remains critical.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
